Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQVS4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,495
Award facts
- Contract value 100% obligated
- $3,494.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $3,494.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, on January 14, 2026. The delivery order is for Xolair 300 mg/2 mL auto-injector (2 mL), a biologic immunosuppressant medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria. The order was issued without a set-aside designation, indicating the contractor competed on an unrestricted basis. Performance is scheduled for completion by February 5, 2026, at the contractor's Park Ridge, Illinois location.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.999 billion ceiling value through December 31, 2036. The PPV-G GEN V contract positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to Department of Defense military healthcare facilities worldwide. The contractor's established performance on numerous delivery orders across diverse therapeutic categories demonstrates its capability to support the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQVS4?
SPE2DR26FQVS4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FQVS4 worth?
The government has obligated $3,495 on SPE2DR26FQVS4.
Is contract SPE2DR26FQVS4 an order under another contract?
Yes. SPE2DR26FQVS4 is a delivery order under SPE2DR25D9247, an indefinite delivery contract.
Was contract SPE2DR26FQVS4 competed?
The extent of competition for SPE2DR26FQVS4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award